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Pentraxin-3 (PTX3) and C-reactive protein (CRP) have been shown to regulate
complement activation in vitro, but their role has not been investigated in complement
consumption in vivo. Thrombotic microangiopathies (TMA) are often accompanied by
complement overactivation and consumption, therefore we analyzed the relation of the
systemic pentraxin levels to the complement profile, laboratory parameters and clinical
outcome of TMA patients. We determined the PTX3 and CRP levels, complement
factor and activation product concentrations in blood samples of 171 subjects with
the diagnosis of typical hemolytic uremic syndrome (STEC-HUS) (N = 34), atypical
HUS (aHUS) (N = 44), secondary TMA (N = 63), thrombotic thrombocytopenic purpura
(TTP) (N = 30) and 69 age-matched healthy individuals. Clinical data, blood count and
chemistry were collected frommedical records. To determine the in vitro effect of PTX3 on
alternative pathway (AP) activation, sheep red blood cell-based hemolytic assay and AP
activity ELISA were used. We found that PTX3 levels were elevated in the acute phase of
STEC-HUS, aHUS and secondary TMA, whereas PTX3 elevation was exceptional is TTP.
Conversely, a significantly higher median CRPwas present in all patient groups compared
to controls. PTX3, but not CRP was associated with signs of complement consumption
in vivo, and PTX3 significantly decreased the AP hemolytic activity in vitro. Our results
provide a detailed description of acute phase-TMA patients’ complement profile linked
to changes in the systemic pentraxin levels that may support further molecular studies
on the function of PTX3 in disease pathogenesis and add to the laboratory assessment
of complement consumption in TMA.
Keywords: pentraxin-3, C-reactive protein, thrombotic microangiopathies, hemolytic uremic syndrome,
thrombotic thrombocytopenic purpura, alternative pathway, complement consumption
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INTRODUCTION
Pentraxin-3 (PTX3) and C-reactive protein (CRP) are fluid phase
pattern recognition molecules that have been shown to
interact with the complement system on multiple levels. PTX3
consists of a unique N-terminal domain (1) and a highly
conserved C-terminal pentraxin-like domain that is shared
with CRP and allows octamer formation of the secreted PTX3
monomers through inter-chain disulfide bonds (2). Prompt
release of PTX3 from neutrophil granulocytes is mediated at
local sites of activation (3), whereas its enduring production
is regulated via gene expression induction in innate immune
cells and endothelial cells (3). Native CRP, a member of the
short-pentraxin protein family, is stored as a pentamer in
the endoplasmic reticulum of resting hepatocytes (4). Upon
inflammatory stimuli CRP is secreted into the circulation and
phosphocholine binding on target cell membranes induces the
disassembly of the pentameric structure to CRP monomers in a
calcium-dependent fashion (4).
PTX3 may facilitate phagocytosis of pathogens and clearance
of cellular debris through the activation of the classical (CP)
and lectin pathways of complement (2) upon binding to surface-
associated mannan-binding lectin (5), ficolins, collectins (6) and
C1q (7). Conversely, its interaction with C1q in the fluid phase
restricts unwanted complement activation (3, 7). PTX3 also
may recruit functionally active complement regulatory proteins,
such as factor H (FH) (8) and C4b-binding protein (C4BP) (9)
to the surface of apoptotic cells, which in turn facilitates C3b
or C4b degradation and phagocytosis. Hence, by FH binding,
PTX3 may prevent alternative pathway (AP) amplification and
activation of the terminal pathway on non-activator surfaces
in vitro (1). However, in vivo disease models of infection and
tissue injury reported contradictory observations on the role of
PTX3 during the inflammatory response. Both endogenous and
exogenous PTX3 were shown to attenuate leukocyte recruitment
and decrease apoptosis in experimental models of kidney
and myocardial tissue injury (10, 11), whereas excess PTX3
was shown to intensify the inflammatory response in disease
models of intestinal ischemia (12, 13) and certain respiratory
pathologies (14).
CRP also has the ability to activate the CP of complement.
Pentameric CRP however, may only bind solid phase C1q when
complexed to phosphocholine (15), with concomitant restrain of
the terminal pathway (16). By contrast, monomeric CRP may
induce excess CP activation both in vitro and in vivo (15, 16),
but at the same time it also allows for CRP to interact with
the complement regulators C4BP, FH, but also with properdin
(15, 17, 18), thus regulating both the CP and AP.
Thrombotic microangiopathies (TMA) are life threatening
conditions that involve acute thrombocytopenia, hemolysis
and organ impairment. Endothelial damage and subsequent
microvascular thrombosis are key pathogenic factors in all forms
of this disease (19, 20), despite differences in the clinical course
andmanagement of TMAswith distinct etiologies.Microvascular
thrombosis has been linked to excessive complement activation
in all forms of TMA (21–23) together with neutrophil activation
and neutrophil extracellular trap (NET) release (24–28), which
may provide excess PTX3 at the site of tissue injury (29) and thus
influence the local complement activity.
Albeit numerous investigations have characterized the
interaction of pentraxins with complement factors in vitro,
no study has been designed so far to explore changes in the
systemic level of pentraxins in complement mediated diseases,
such as TMAs. Therefore, we performed a case-control study to
determine the systemic levels of PTX3 and CRP in patients at the
acute phase and remission of TMA. We explored the association
between TMA-related complement consumption and circulatory
pentraxin levels in vivo as well as the direct effect of PTX3 on
AP activation in vitro, to reveal the potential role of pentraxins
in complement mediated tissue injury. We further analyzed the
relationship between the systemic level of pentraxins and TMA
etiology, the clinical outcome of patients and classical laboratory
markers of TMA.
METHODS
Patient Selection and Sample Collection
171 TMA patients with acute disease flare were enrolled in this
study. Serum and plasma samples from all subjects were collected
prior to the start of plasma exchange therapy; however, in 16
cases fresh frozen plasma had been administered to the patients
prior to sampling. For appropriate comparison, 69 age-matched
healthy individuals were selected, none of whom showed clinical
or laboratory signs of TMA or an acute phase reaction that
could have influenced the measured laboratory parameters.
Diagnosis of TMA was established based on laboratory signs of
thrombocytopenia (<150 G/L), and microangiopathic hemolytic
anemia. Patients were included in the study only if all of the
above criteria were met. For stratification of patients by disease
etiology the following groups were formed: STEC-HUS (N =
34), aHUS (N = 44), secondary TMA (N = 63) and TTP
(N = 30) (Figure 1), based on additional diagnostic criteria
detailed in the Supplementary Material. Exclusion criteria were
ongoing plasma exchange or complement inhibitory therapy
at the time of sample collection (during the first acute flare),
or the lack of available blood sample. For additional details
on the study population please see the methods section of
the Supplementary Material. This study was carried out in
conformity with the Helsinki Declaration. Written informed
consent was obtained from all participants, and the study was
approved by the Scientific and Research Ethics Committee of the
Medical Research Council (ETT TUKEB) in Budapest, Hungary
(8361-1/2011-EKU).
Determination of Laboratory Parameters
Complement activity-, component-, regulator-, and activation
product determinations, CRP and PTX3 measurements were
performed in this study. The AP activity was determined
with the commercially available WIESLAB Alternative pathway
ELISA kit (EuroDiagnostica, Malmö, Sweden), while total
complement classical pathway activity was assessed using the
sheep-erythrocyte hemolytic titration test. C3, C4 and hsCRP
were measured by turbidimetry (Beckman Coulter, Brea, CA),
complement factors B, and I were determined by radial
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FIGURE 1 | Representation of TMA disease etiology in the studied population. The number of participants per group (N) is shown as proportion of a whole. HUS,
hemolytic uremic syndrome; STEC-HUS, Shiga-like toxin associated HUS; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura; Tx,
transplantation.
immunodiffusion assay. The level of the complement regulators
C1q and FH and the titer of the anti-FH antibodies were
measured using in-house ELISA techniques, described in detail
elsewhere (22, 30, 31). A disintegrin and metalloproteinase
with a thrombospondin type 1 motif member 13 (ADAMTS13)
activity was evaluated by the application of the fluorogenic
substrate FRETS-VWF73 (22). Commercially available kits were
used to assess the levels of the complement activation products
soluble C5b-9 (sC5b-9) and C3a (C3a des-arg) (Quidel, San
Diego, CA) and for the measurement of PTX3 (R&D systems
Minneapolis, MN). For the determination of CRP, PTX3,
complement factor levels and pathway activities patient’s sera
were obtained. The complement activation products (sC5b-9
and C3a) were determined from EDTA anticoagulated plasma,
whereas the ADAMTS13 activity was evaluated from sodium-
citrate-anticoagulated plasma of the patients.
In vitro Assessment of PTX3 Effect on AP
Activation
We applied normal human serum (NHS) with additional
recombinant human PTX3 in two established methods for
the assessment of AP activity: the WIESLAB AP ELISA kit
(EuroDiagnostica, Malmö, Sweden) and the C3 nephritic factor
hemolytic assay (32), with modifications. The C3 nephritic
factor assay was performed on washed sheep erythrocytes,
where patient’s samples were replaced by NHS spiked with
recombinant human PTX3 (R&D systems Minneapolis, MN,
USA) in gradually decreasing concentrations. Following a 20-
min incubation of PTX3 with NHS, the solution was added
to sheep erythrocytes. The formation of the C3 convertase was
allowed within a 10-min incubation time at 30
◦
C, and assembly
of the terminal pathway membrane attack complex was achieved
by the addition of undiluted rat serum to the cells, following
multiple washes. After incubation at 37
◦
C for 60min, the extent
of hemolysis was detected by reading the optical density (OD)
at 412 nm. The effect of PTX3 on the assembly of C5b-9 on
a plastic surface was assessed with the WIESLAB Alternative
pathway ELISA kit (EuroDiagnostica, Malmö, Sweden). Similarly
to the above, patient’s sera were replaced by PTX3 spiked
NHS, otherwise the assay was performed according to the
manufacturer’s instructions. To allow comparison of data, the
hemolytic or AP activities in each experiment were expressed
as ratio of the reference (mean OD of NHS with buffer control)
in percentage.
Statistical Analysis
Data analysis was performed using the GraphPad Prism version
6.00 (GraphPad Software, La Jolla, CA, www.graphpad.com). The
statistical analysis applied for data comparison is indicated in
each figure legend and detailed in the Supplementary Material.
RESULTS
Patient Characteristics
This study was performed to determine the systemic level of CRP
and PTX3 in 171 TMA patients in acute disease flare and to
investigate the role of PTX3 in complement dysregulation in vivo
compared to 69 age and sex-matched healthy individuals. Basic
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clinical and laboratory characteristics of the patients and controls
are summarized in Table 1.
Our study group consisted of TMA patients with the following
etiologies: STEC-HUS (N = 34), aHUS (N = 44), secondary
TMA (N = 63), and TTP (N = 30) (Figure 1). Over 90% of
the admitted patients presented with the first acute episode
of the disease. Blood samples were obtained from all patients
preceding the start of plasma exchange or complement inhibitory
therapy, although 16 patients received fresh frozen plasma prior
to sampling. Figure 1 shows the distribution of patients with
various etiologies in the aHUS and secondary TMA groups.
All acute phase-TMA patients presented with laboratory
signs of hemolysis and thrombocytopenia (<150 G/L), with
the lowest median platelet count (i.e., 16 G/L) in the TTP
subgroup. ADAMTS13 activity was decreased in 79% of the
patients and ADAMTS13 deficiency was present in all of the
TTP patients. Organ involvement manifested in clinical and
laboratory signs of kidney damage or neurological symptoms
as a sign of central nervous system involvement in most of
the TMA patients. Classical laboratory parameters indicative of
ongoing TMA in each of the study groups are summarized in
Supplementary Table 1.
Pentraxin Levels in Acute Phase-TMA and
Their Relation to the Laboratory Markers
of Disease and Clinical Characteristics of
Patients
We measured a significantly elevated median PTX3 level in
acute phase-TMA compared to healthy controls (Figure 2A),
with an elevated systemic PTX3 level in 64% of the acute
phase TMA patients. CRP levels were also higher, exceeding
TABLE 1 | Characteristics of the TMA patients and healthy controls.
Characteristics analyzed TMA Healthy controls Result of statistical comparison
Number of individuals enrolled 171 69 NA
Age 35.2 (7.7–56.9) 33.0 (18.7–41.0) P = 0.608
Sex (male/female in %) 43/57 48/52 NA
First acute episode (%) 93.6 NA NA
31-days mortality (%) 11.7 0 NA
Complement C3 < 0.9 g/L (%) 49.7 0 NA
Complement FH < 250 mg/L (%) 25.7 0 NA
LABORATORY PARAMETERS INDICATIVE OF ONGOING TMA
Red blood cell count (109/L) 2.9 (2.6–3.4) 4.9 (4.6–5.2) p < 0.001
Hemoglobin (g/L) 85 (75–97) 141 (134–152) p < 0.001
Platelet count (109/L) 46 (22–75) 262 (235–309) p < 0.001
Lactate dehydrogenase (U/L) 1,819 (893–3,051) Not done NA
Creatinine (µmol/L) 188 (86–320) 71 (64–78) p < 0.001
Carbamide (mmol/L) 16.9 (10.9–25.9) 4.5 (3.8–5.6) p < 0.001
PENTRAXIN LEVELS AND WHITE BLOOD CELL PROFILE
PTX3 level (µg/L) 5.19 (2.08–13.17) 1.08 (0.75–1.66) p < 0.001
CRP level (mg/L) 16.9 (4.3–72.0) 1.4 (0.8–2.0) p < 0.001
White blood cell count (G/L) 10.4 (7.1–15.3) 6.5 (5.4–7.9) p < 0.001
Absolute neutrophil count (G/L) 7.1 (4.8–12.4) 4.0 (3.0–4.7) p < 0.001
Absolute lymphocyte count (G/L) 1.4 (0.8–2.6) 2.0 (1.8–2.4) p < 0.001
COMPLEMENT PARAMETERS
ADAMTS13 activity (%) (Reference range: 67–147%) 38 (17–54) Not done NA
Classical pathway activity (CH50/ml) 57 (45–71) 70 (62–77) p < 0.001
Alternative pathway activity (%) 86 (56–101) 101 (78–117) p < 0.001
C3 level (g/L) 0.90 (0.68–1.15) 1.26 (1.18–1.47) p < 0.001
C4 level (g/L) 0.23 (0.14–0.32) 0.34 (0.27–0.40) p < 0.001
Factor H level (mg/L) 390 (245–513) 560 (462–692) p < 0.001
Factor I level (%) 98 (81–123) 102 (92–108) p = 0.192
Factor B level (%) 98 (73–116) 101 (91–113) p = 0.791
C1q level (mg/L) 87 (56–112) 100 (80–124) p = 0.020
sC5b-9 level (ng/mL) (Reference range: 110–252 ng/mL) 352 (265–517) Not done NA
C3a level (ng/mL) (Reference range: 70–270 ng/mL) 171 (120–259) Not done NA
Characteristics and laboratory data of the TMA patients and healthy controls. Data are shown as median with interquartile range, results of statistical comparison are indicated with the
respective p-value of the Mann-Whitney test. ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CRP, C-reactive protein; FH, factor H;
NA, not applicable; PTX3, pentraxin-3; sC5b-9, soluble C5b-9; TMA, thrombotic microangiopathy.
Frontiers in Immunology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 240
Trojnar et al. PTX3 and CRP in TMA
FIGURE 2 | PTX3 and CRP levels in acute TMA vs. healthy controls. (A,B) PTX3 and CRP levels of TMA patients at the acute disease onset compared to pentraxin
levels of healthy individuals. (C,D) PTX3 and CRP levels of acute phase-TMA patients grouped by disease etiology. Data are expressed as mean of technical
duplicates, the horizontal line indicates the median of each group, while an intermittent line shows the calculated cutoff of each pentraxin, respectively. Statistical
analysis was performed with the Mann Whitney test (A,B) or the Kruskal-Wallis test corrected for multiple comparisons using the Dunn’s post hoc test (C,D),
respectively. Statistical significance is indicated by asterisks (****p < 0.0001). aHUS, atypical hemolytic uremic syndrome; CRP, C-reactive protein; PTX3, pentraxin-3;
STEC-HUS, Shiga-like toxin associated HUS; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.
the upper limit of normal range (5 mg/L) in 70% of TMA
patients (Figure 2B). The calculated cutoff of CRP levels (5.01
mg/L) was equivalent to the upper limit of normal range
(5 mg/L) used in our laboratory in frames of diagnostics,
whereas the cutoff of PTX3 levels was determined based on
the levels measured in the healthy control group and set as
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3.40 µg/L (mean + 2 times the standard deviation of healthy
controls).
Elevated PTX3 and CRP levels could be detected in all etiology
groups of TMA, although PTX3 elevation was exceptional in
TTP, despite the elevated CRP level in 53% of the patients of
this subgroup (Figures 2C,D). With further subdivision of the
study groups, we found that the elevation of both pentraxins
was independent of the molecular background in aHUS, since
in each of the distinct aHUS subgroups PTX3 or CRP levels
were significantly elevated compared to healthy controls (all
p < 0.05, Mann-Whitney test) (Figures 3A,B), and we detected
similar pentraxin levels in secondary TMAs with distinct
etiologies, too (data not shown). PTX3 levels were associated
with markers of disease activity and organ damage in TMA. We
observed a positive correlation between lactate dehydrogenase
and PTX3 levels, and a weaker yet significant correlation of
the platelet count and laboratory signs of kidney damage to
PTX3. By contrast, association between CRP and disease activity
was not present, except a significant positive correlation to
creatinine levels (Table 2). The parameters presented in Table 2
were entered into two multiple regression models to explore
relationship between them and PTX3 or CRP, respectively. LDH
(standardized regression coefficient beta = 0.299) turned out
to be significant predictor of PTX3 in the multivariable model,
whereas platelet and kidney function measures did not. For
CRP, significant predictors were hemoglobin (beta = 0.183),
platelet number (beta = −0.179) and creatinine (beta = 0.338)
levels. Since platelet count is a reliable marker of disease activity
in TMA, we further explored its relationship to the systemic
pentraxin levels by grouped analysis of patients according
to platelet counts at the time of admission. We found that
irrespective of the classification, median PTX3 and CRP levels
of all subgroups remained significantly elevated compared to
healthy controls (Supplementary Figure 1). Furthermore, PTX3
and CRP showed a strong positive correlation to each other
and to markers of systemic inflammation such as the white
blood cell count and absolute neutrophil count of the patients
(Supplementary Figures 2, 3). In the 16 FFP-treated patients
enrolled in this study, administration of FFP did not results in
an improvement of the clinical status or the classical laboratory
signs of TMA until the time point of blood sample collection. We
performed all our analysis with the exclusion of the FFP-treated
patients as well, and it did not change any of our conclusions on
the correlations observed at the acute phase of TMA.
Elevated Pentraxin Levels Normalize in
Disease Remission
We obtained follow-up samples from 31 aHUS patients and
19 of the TTP patients. In over 80% of aHUS both PTX3 and
CRP levels decreased in remission compared to the paired acute
phase samples, but the extent of decline did not reach statistical
significance in patients with no clarified molecular background
of the disease (Figures 3A,B). The median PTX3 level also
remained significantly higher in aHUS remission compared to
the control group, while the CRP levels in remission were
similar to that of healthy controls (Supplementary Figure 4).
The initially low PTX3 levels of TTP patients showed no
remarkable difference in remission, and the CRP levels also
normalized in over 80% of the cases (Supplementary Figure 5).
Association of the Median PTX3 Level With
the Acute Phase Mortality
The overall 11.7% acute phase mortality arose from the high
mortality rate of the secondary TMA group, which exceeded 30%
within a 31-days period. No deaths occurred in the STEC-HUS
or aHUS study groups and one patient died in the TTP group.
The median CRP levels did not differ significantly in secondary
TMA patients who survived the acute phase compared to those
who did not, but the median PTX3 level was significantly higher
in the deceased individuals compared to those who survived the
first month of the TMA episode (Figures 4A,B). The optimum
PTX3 cut-point was 9µg/mL to differentiate patients who died
during follow up, from those who survived [odd’s ratio 3.08 (95%
CI 1.02–9.33)]. One-by-one adjustment for key activity indicators
showed that high PTX3 levels are hemoglobin and creatinine
independent predictors of mortality, whereas dependent on
platelet and LDH levels.
Signs of Complement Consumption in
Acute Phase-TMA and Their Association
With the Systemic Pentraxin Levels
Nearly 50% of the TMA patients presented with decreased C3
levels indicative of complement consumption (Table 1), while
only 9% of the patients (15/171) showed no signs of complement
alteration (with C3, C4, FH, C1q, factor I and factor B levels,
CP and AP activities, and complement activation product levels
within the laboratory normal range). To assess whether elevated
pentraxin levels were associated with complement consumption
in the acute phase of TMA, we grouped the patients based on
PTX3 and CRP levels and observed a strong linkage between
the gradual increase in PTX3 and signs of complement AP
and CP consumption (Figure 5 and Supplementary Table 2). As
a result of complement overactivation and complement factor
consumption, both C3 and C4 levels were significantly lower in
patients with PTX3 above 20 µg/L compared to those below 5
µg/L. If the relationships between decreased C3 and C4 levels
to the elevated PTX3 (Figures 5A,C) were further analyzed in
subgroups of patients stratified according to the most important
confounder, i.e., LDH level (Supplementary Figure 6), similar
associations were observed. Although the gradual increase of
PTX3 was not accompanied by a decrease in the FH levels,
complement CP and AP activities were significantly lower in
patients with PTX3 above 20 µg/L compared to those with PTX3
below 5 µg/L. Moreover, patients with a PTX3 level exceeding
20 µg/L had a median AP and CP activity below the normal
range indicating explicit complement consumption. By contrast,
CRP levels did not show an association with any of the measured
complement activity parameters.
Influence of PTX3 on AP Activation in vitro
In vivo complement consumption was accompanied by a gradual
increase in the systemic PTX3 level in our acute phase-TMA
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FIGURE 3 | PTX3 and CRP levels in aHUS acute phase and remission. PTX3 (A) and CRP (B) levels of aHUS patients are shown in the acute phase (black squares)
and in remission (empty squares) with a continuous line connecting the respective sample pairs, while the medians of each group are indicated by a horizontal line.
Half of the patients (N = 22, left) had a confirmed likely pathogenic mutation, 11 patients presented with anti-factor H antibodies (middle) and by the rest (N = 11,
right) no likely pathogenic mutation has been identified in the complement genes (CFH, CFHR5, CFI, CD46, C3, CFB), THBD or DGKE. Data points represent mean of
technical duplicates, statistical analysis was performed with the Wilcoxon-signed rank test, statistical significance is indicated by asterisks (**p < 0.01; ***p < 0.001).
aHUS, atypical hemolytic uremic syndrome; CRP, C-reactive protein; PTX3, pentraxin-3.
patients. To explore the functional relevance of this phenomenon
we tested whether PTX3 attenuates or stimulates the AP activity
on the cellular surface. In a modified hemolytic assay (used to
determine the C3 nephritic factor level) we built up the AP
convertase on sheep erythrocytes and determined the hemolytic
activity of NHS with the addition of recombinant human
PTX3 or buffer control, respectively (Figure 6A). We found that
addition of PTX3 significantly decreased the activity of the AP
C3-convertase on sheep red blood cells. Conversely, addition of
PTX3 to NHS did not influence AP activity on the surface of
ELISA plates. Hence, no remarkable change was detected in C9
deposition through lipopolysaccharide (LPS)-induced activation
of the AP (Figure 6B), whereas PTX3 alone did not bind to LPS
in the ELISA wells (data not shown).
DISCUSSION
Our study investigated the role of PTX3 and CRP in association
with complement consumption in the acute phase of TMA.
We provide a detailed description of acute phase-TMA patients’
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TABLE 2 | Correlation of the systemic pentraxin levels to laboratory markers of TMA.
Laboratory parameters analyzed PTX3 CRP
Spearman r p-value N Spearman r p-value N
Red blood cell count 0.08785 0.3380 121 0.02669 0.7714 121
Hemoglobin 0.007054 0.9329 145 0.07903 0.3447 145
Platelet count 0.1975 0.0161 148 −0.1107 0.1806 148
Lactate dehydrogenase 0.299 0.0004 134 0.003968 0.9637 134
Creatinine 0.2421 0.0023 156 0.2266 0.0045 156
Carbamide 0.2011 0.0257 123 0.1377 0.1289 123
Spearman correlation analysis of PTX3 and CRP levels to laboratory markers of hemolysis, thrombocytopenia and kidney damage, characteristic to acute phase-TMA. Statistical analysis
was performed by the Spearman correlation test, obtained r and p-values are indicated by each parameter, with the number of pairs analyzed. Significant correlations are highlighted
in bold. Please note that blood count and chemistry data were not accessible by all the enrolled patients, therefore the correlation analyses might include less than the total number of
patients (N = 171) in this study, CRP. C-reactive protein; PTX3, pentraxin-3; TMA, thrombotic microangiopathy.
FIGURE 4 | Association of the systemic pentraxin levels to acute phase mortality in secondary TMA. PTX3 (A) and CRP (B) levels of acute phase secondary TMA
patients are shown, grouped based on the 31-day survival of patients (deceased, black triangles; survived, white triangles). Data are expressed as mean of technical
duplicates, the horizontal line indicates the median of each group, while an intermittent line shows the calculated cutoff of each pentraxin, respectively. Statistical
analysis was performed with the Mann-Whitney test. Statistical significance is indicated by asterisks (**p < 0.01). CRP, C-reactive protein; PTX3, pentraxin-3; TMA,
thrombotic microangiopathy.
complement profile linked to changes in the systemic pentraxin
levels.We report that PTX3 elevation is present in the acute phase
of STEC-HUS, aHUS and secondary TMA but is exceptional
in TTP. Conversely, an elevation in the systemic CRP level
is present regardless of disease etiology in the acute phase of
TMA (Figure 2). Disease remission in aHUS was accompanied
by a decline in the level of both pentraxins (Figure 3).
However, while CRP decreased to values observed in healthy
individuals, the median PTX3 level remained significantly higher
in aHUS compared to controls (Supplementary Figure 4). In the
remission of TTP no notable alteration of the PTX3 levels could
be recorded (Supplementary Figure 5). We observed the highest
acute phase mortality in secondary TMA patients, which was
associated with high PTX3 but not CRP levels (Figure 4). TMA
was accompanied by laboratory signs of complement activation
and consumption in the majority of our patients. We show for
the first time that AP and CP consumption is associated with
elevated PTX3 in the acute phase of TMA (Figure 5). To explore
a potential mechanism in the background of this observation, we
confirmed in vitro that PTX3 limits AP activity on the surface
of red blood cells, with no effect on terminal pathway assembly
during LPS-induced AP activation on ELISA plates (Figure 6).
Microthrombus formation in TMA results in extensive
inflammation that involves turnover of the complement and
coagulation cascades together with the activation of innate
immunity (21). The observed elevation of both pentraxins in
acute phase-TMA and their strong positive correlation to the
white blood cell and absolute neutrophil counts suggests that
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FIGURE 5 | Association of the systemic pentraxin levels with laboratory signs of complement consumption. The degree of complement activation and consumption
was assessed from complement factor levels (A–F: C3, C4, FH) and complement activity parameters (G–J) in TMA patients subdivided based on the measured
systemic PTX3 or CRP levels, respectively. Data are expressed as mean of technical duplicates, the horizontal lines show the median of each group and the laboratory
normal range is indicated with gray shading. The color of each data point indicates the specific form of TMA corresponding to Figure 1 (brown, aHUS; red,
STEC-HUS; black, secondary TMA; gray, TTP). Statistical analysis was performed with the Kruskal-Wallis test corrected for multiple comparisons using the Dunn’s
post hoc test. ANOVA p < 0.0001, p = 0.1285, p = 0.0002, p = 0.6713, p = 0.0358, p = 0.2173, p < 0.0001, p = 0.0717, p = 0.0001, p = 0.053 for (A–J),
statistical significance of the Dunn’s tests are indicated by asterisks (***p < 0.001, ****p < 0.0001) on the respective figure panels (A–J). aHUS, atypical hemolytic
uremic syndrome; CRP, C-reactive protein; PTX3, pentraxin-3; STEC-HUS, Shiga-like toxin associated HUS; TMA, thrombotic microangiopathy; TTP, thrombotic
thrombocytopenic purpura.
FIGURE 6 | Effect of PTX3 on AP activity in vitro. The effect of recombinant human PTX3 on AP hemolytic activity (A) and AP-mediated C9 deposition (B) is shown in
percent compared to buffer control added to pooled serum of healthy individuals. Data represent mean of 3 times repeated experiments with technical duplicates,
error bars indicate the standard error of mean. Statistical analysis was performed with the Kruskal-Wallis test corrected for multiple comparisons using the Dunn’s post
hoc test. Statistical significance is indicated by asterisks (*p < 0.05; ***p < 0.001). AP, alternative pathway; PTX3, pentraxin-3.
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PTX3 and CRP production is induced in frames of the ongoing
inflammatory response (Supplementary Figures 2, 3). TMAs
have recently been linked to neutrophil cell activation and NET
formation (24–28), as a component of which PTX3 may be
released on demand from leukocyte infiltrates that accumulate at
the site of endothelial damage (3, 29). Furthermore, local levels
of PTX3 may increase via its production by injured endothelial
cells (3), hence providing a possible dual-source of PTX3 during
the acute phase of TMA. Conversely, increased CRP production
may be attributed to the induction of a systemic inflammatory
response that induces the release of acute phase proteins.
In approximately 60% of aHUS cases mutations to
the complement genes or antibodies directed against the
complement regulator FH account for the pathophysiological
process leading to AP dysregulation and consumption (33, 34),
whereas in the remaining one-third of the cases the molecular
background remains unrevealed. Our aHUS cohort had a
somewhat higher representation of autoimmune aHUS (25 vs.
10%) and a relatively small proportion of unexplained cases (25
vs. 30–40%) compared to the previously reported prevalence
(33, 34). We had a notable number of patients with low FH
level in our patient cohort. This arose from FH mutations and
antibodies in aHUS, albeit patients with a low FH level were
also present in STEC-HUS, secondary TMA and TTP, indicating
the presence of complement dysregulation in multiple forms
of TMA. Nonetheless, elevated pentraxin levels were present
in all aHUS subgroups independent of the molecular etiology.
PTX3 and CRP elevation was also prominent in STEC-HUS
and secondary TMA, regardless of the heterogenic etiological
background of the patients. However, PTX3 elevation was
exceptional in TTP, albeit neutrophil cell activation together with
complement dysregulation have been described in TTP (22, 28).
Laboratory signs of kidney damage were also absent in 70% of
the TTP patients, while most patients with other forms of TMA
presented with a varying degree of kidney injury. Both acute
and chronic kidney damage have been linked to the elevation of
PTX3 (35), the lack of which in TTP could provide a possible
explanation for the absence of PTX3 elevation in TTP. However,
it cannot be excluded that additional factors arising from the
distinct pathogenesis of TTP (34) have also contributed to the
observed difference.
Secondary TMA patients in our study cohort had an overall
30.2% in-hospital mortality, which is comparable to observations
reported in literature (23, 36). Acute phase disease mortality
was associated with a higher median PTX3 level in secondary
TMA, and this relationship was independent of the hemoglobin
and creatinine levels, but was non-independent of platelet
and LDH. The difference between median CRP levels did not
reach statistical significance in deceased patients compared to
those who survived the first month of the TMA episode.
This observation conforms published reports in regard to the
association of PTX3 to acute disease mortality in multiple
conditions including severe sepsis (37, 38), ventilation assisted
pneumonia (39) and acute aortic type A dissection (40). Besides,
PTX3 was reported to be a long-term prognostic marker of
mortality in patients undergoing hemodialysis (41) and of
cardiovascular death in patients with renal disease (42), whereas
some studies even place PTX3 superior to CRP as a predictor of
mortality (39), endothelial dysfunction (43) or indicator of local
inflammatory response following vascular injury (44).
Even though both pentraxins have been described to
interact with the complement system in vitro (1, 2), we only
found an association between laboratory signs of complement
consumption and elevated PTX3 in the acute phase of TMA. The
net result of the PTX3-complement interaction is proposed to
be restrain of complement-mediated damage on non-activator
surfaces and stimulation of phagocytosis and clearance of cellular
debris (1, 2). In vivo experimental models of tissue damage
however, reported inconclusive data on the overall impact
of PTX3 on tissue recovery. In murine models of ischemia-
reperfusion injury both endogenous and exogenous PTX3 were
described to alleviate leukocyte recruitment following renal
ischemia (10), while the lack of PTX3 was associated with a
higher degree of apoptosis and C3 deposition in damaged cardiac
tissue (11). Nevertheless, others reported that the overexpression
or external admission of PTX3 exacerbated the post-ischemic
intestinal and remote pulmonary tissue damage (12, 13). In
humans PTX3 has been shown to correlate with surrogate
markers of disease severity in cardiovascular and renal diseases
(35, 45, 46) and molecular characterization of this association
suggests that PTX3 is involved in the fine tuning of inflammation
with an overall tissue-protective effect (47, 48).
In endothelial damage associated with TMA, although NET
formation may promote thrombosis and complement activation
(49), as a NET component (29) PTX3 may recruit the
complement regulator FH (8) and limit the expansion of tissue
damage mediated by the AP. The potential regulatory role of
PTX3 on AP activity is suggested by experimental evidence
describing FH recruitment by PTX3 (8, 50) to the damaged cell
surface, while the presence of anti-FH antibodies or mutations
of the complement regulator have been linked to an impaired
FH-PTX3 interaction that may aggravate the endothelial damage
in aHUS (50). To better understand the potential role of PTX3
elevation in TMA, we measured the changes of AP activity in
the presence or absence of external PTX3 using two distinct in
vitro approaches. First, to determine the AP hemolytic activity,
we built up the C3 convertase on sheep erythrocytes under
conditions allowing for AP activation only. Second, we assessed
C9 generation on the surface of ELISA plates via LPS-induced
AP activation, with or without additional PTX3. Based on the
gradual decline of the hemolytic activity parallel to the increment
of PTX3 concentration in pooled human serum, we conclude that
local release of PTX3 may indeed play an important role in the
limitation of AP activity. However, based on previously published
observations on the interaction of PTX3 with the regulators of
complement (8, 9, 50), restrain of the AP activity by PTX3 is
most probably due to an indirect effect (e.g., recruitment of
complement regulators), which requires cellular attachment of
the PRM, rather than direct inhibition of the activation pathway.
This hypothesis is also supported by the observed lack of AP
restrain, when the activation was induced on the surface of an
ELISA plate, however detailed molecular investigation of this
phenomenon would be necessary to identify each complement
factor involved in the regulatory effect. Nonetheless, the observed
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restrain of the AP indicates that local release of PTX3 could
possibly attenuate complement activity and hence potentially
limit the ongoing endothelial damage in TMA patients.
Finally, the lack of correlation between CRP levels and
complement consumption could be attributed to the fact,
that CRP production is induced in the liver in frames of a
systemic inflammatory response that may not closely reflect the
degree of local endothelial damage and subsequent complement
consumption. However, in vitro evidence suggests that through
the binding of complement regulators and the restrain of excess
terminal pathway activity, CRP as well as PTX3 are able to
regulate the AP and CP of complement (1, 15–18).
In conclusion, we report the association of PTX3 elevation
with complement overactivation and consumption in TMA.
The regulatory role of PTX3 on AP hemolytic activity in vitro
suggests that PTX3 is an adjunct factor in the prevention
of excess endothelial damage in TMA. Our observations are
in line with previously published in vitro data describing the
interaction of PTX3 and individual complement factors, and
add to in vivo investigations emphasizing the potential tissue-
protective role of PTX3. This is the first study where the
association of PTX3 and CRP elevation has been investigated
in a complement mediated disease in vivo, and thus our
results provide a missing link between the numerous in vitro
observations that described the interaction of PTX3 with the
complement system under defined experimental conditions.
On the other hand, our observations may indicate a potential
practical use of PTX3 determination as a biomarker and
determinant of complement consumption in the acute phase
of TMA. However, apparent limitations of our study are
the retrospective enrollment of patients and the rare nature
of this disease that together may have caused some of our
analyses to be underpowered. The limited number of study
subjects and subsequently low case and event numbers in this
study precluded multivariate analysis in different etiology based
subgroups of TMAs, therefore some of our observation may
represent overestimation of true effects due to the lack of
adjustment for important clinical and/or laboratory covariates.
Therefore, independent confirmation of our observations is
necessary before firm conclusions can be reached on the
contribution of PTX3 to the pathogenesis of TMA. Nonetheless,
the reported association of elevated PTX3 levels and complement
consumption may initiate further investigations to understand
the exact role of PTX3 in TMA pathogenesis and may
aid the better understanding of the heterogeneous clinical
course of TMA.
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